Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;20(5):108.
doi: 10.1007/s11306-024-02171-6.

Cognitive improvements linked to lysophosphatidylethanolamine after olanzapine treatment in drug-naïve first-episode schizophrenia

Juanhua Li  1   2 , Yuanguang Xu  3 , Xin Wang  3 , Caixing Liu  3 , Zezhi Li  1   2 , Meihong Xiu  4 , Hongying Chen  5
Affiliations

Cognitive improvements linked to lysophosphatidylethanolamine after olanzapine treatment in drug-naïve first-episode schizophrenia

Juanhua Li et al. Metabolomics. .

Abstract

Background: Cognitive impairments are a hallmark symptom of schizophrenia (SCZ). Phosphatidylethanolamine (PE) is the second most abundant phospholipid in mammalian cells, yet its role in cognitive deficits remains unexplored. The aim of this study was to investigate the association between plasma LysoPE and cognitive improvements following olanzapine monotherapy in drug-naïve first-episode (DNFE) SCZ patients.

Methods: Twenty-five female DNFE SCZ patients were treated with olanzapine for four weeks, and cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline and after the 4-week follow-up. Utilizing an untargeted ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabolomics approach, we measured LysoPE concentrations.

Results: Significant improvements in immediate and delayed memory domains were observed post-treatment. We identified nine differential LysoPE species after olanzapine monotherapy, with increased concentrations for all LysoPE except LysoPE (22:6). Elevated LysoPE (22:1) concentration positively correlated with cognitive improvement in patients. Baseline LysoPE (16:1) emerged as a predictive factor for cognitive improvement following olanzapine monotherapy.

Conclusions: This study offers preliminary evidence for the involvement of LysoPE in cognitive improvements observed in drug-naïve first-episode SCZ patients after olanzapine treatment.

Keywords: Cognitive improvement; Longitudinal study; Lysophosphatidylethanolamine; Olanzapine; Schizophrenia.

PubMed Disclaimer

References

    1. Baldez, D. P., Biazus, T. B., Rabelo-da-Ponte, F. D., Nogaro, G. P., Martins, D. S., Kunz, M. (2021). The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 126(2), 265–275
    1. Barnett, R., & Schizophrenia (2018). Lancet, 391(10121):648. - DOI - PubMed
    1. Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., et al. (2000). Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. American Journal of Psychiatry, 157(4), 549–559. - DOI - PubMed
    1. Burschinski, A., Schneider-Thoma, J., Chiocchia, V., Schestag, K., Wang, D., Siafis, S., et al. (2023). Metabolic side effects in persons with schizophrenia during mid‐to long‐term treatment with antipsychotics: A network meta‐analysis of randomized controlled trials. World Psychiatry, 22(1), 116–128. - DOI - PubMed - PMC
    1. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 14(2), 87–96. - DOI - PubMed

LinkOut - more resources